STAT July 23, 2024
Allison DeAngelis

When Sanjaya Singh left Johnson & Johnson in 2021, his former colleague Peter Lebowitz paid close attention.

Singh had been a mainstay in the immunology and oncology fields, helping to invent the blockbuster drug Skyrizi and several other treatments during stints at Johnson & Johnson and Boehringer Ingelheim. “If Sanjaya Singh is doing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Sanofi, expanding in radiopharma, strikes a joint venture deal
Sage to cut one-third of workforce, streamline drug pipeline
After rejections, AbbVie secures approval for Parkinson’s drug
Wave surges on first RNA editing data in humans
Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe

Share This Article